KCNN4 and early-onset autosomal dominant Alzheimer disease: KCa3.1 inhibitors accordingly reduce neuroinflammation and ameliorate pathology in rodent models of Alzheimer’s disease [35], traumatic brain injury [61], and multiple sclerosis [62].